Polymer-free stents for percutaneous coronary intervention in diabetic patients: a systematic review and meta-analysis

References

• Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117(15):1945–1954. doi:10.1161/CIRCULATIONAHA.107.720847
   PubMed Web of Science ®Google Scholar
• Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in Type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–2502. doi:10.1161/CIRCULATIONAHA.116.022194
   PubMed Web of Science ®Google Scholar
• Gori T, Polimeni A, Indolfi C, et al. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol. 2019;16(4):243–256. doi:10.1038/s41569-018-0118-5
   PubMed Web of Science ®Google Scholar
• Ullrich H, Olschewski M, Münzel T, et al. Coronary in-stent restenosis: predictors and treatment. Dtsch Arztebl Int. 2021;118(38):637–644. doi:10.3238/arztebl.m2021.0254
   PubMed Web of Science ®Google Scholar
• Nogic J, Nerlekar N, Soon K, et al. Diabetes mellitus is independently associated with early stent thrombosis in patients undergoing drug eluting stent implantation: analysis from the Victorian cardiac outcomes registry. Catheter Cardiovasc Interv. 2022;99(3):554–562. doi:10.1002/ccd.29913
   PubMed Web of Science ®Google Scholar
• Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. J Am Med Assoc. 2007;298(7):765–775. doi:10.1001/jama.298.7.765
   PubMed Web of Science ®Google Scholar
• Hausleiter J, Kastrati A, Wessely R, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005;26(15):1475–1481. doi:10.1093/eurheartj/ehi405
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27(7):1500–1510. doi:10.1161/ATVBAHA.107.144220
   PubMed Web of Science ®Google Scholar
• Byrne RA, Mehilli J, Iijima R, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs polymer-based drug-eluting stents. Eur Heart J. 2009;30(8):923–931. doi:10.1093/eurheartj/ehp044
   PubMed Web of Science ®Google Scholar
• Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) trial. Circulation. 2011;124(5):624–632. doi:10.1161/CIRCULATIONAHA.111.026732
   PubMed Web of Science ®Google Scholar
• King L, Byrne RA, Mehilli J, et al. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheter Cardiovasc Interv. 2013;81(1):E23–28. doi:10.1002/ccd.24375
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–2047. doi:10.1056/NEJMoa1503943
   PubMed Web of Science ®Google Scholar
• Krackhardt F, Kočka V, Waliszewski MW, et al. Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart. 2017;4(2):e000592. doi:10.1136/openhrt-2017-000592
   PubMedGoogle Scholar
• Verdoia M, Kedhi E, Suryapranata H, et al. Polymer-free vs. polymer-coated drug-eluting stents for the treatment of coronary artery disease: a meta-analysis of 16 randomized trials. Cardiovasc Revasc Med. 2020;21(6):745–753. doi:10.1016/j.carrev.2019.10.017
   PubMed Web of Science ®Google Scholar
• Stiermaier T, Heinz A, Schloma D, et al. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). Catheter Cardiovasc Interv. 2014;83(3):418–424. doi:10.1002/ccd.25131
   PubMed Web of Science ®Google Scholar
• Ascencio-Lemus MG, Romaguera R, Brugaletta S, et al. Amphilimus- versus everolimus-eluting stents in patients with diabetes mellitus: 5-year follow-up of the RESERVOIR trial. Cardiovasc Revasc Med. 2022;43:130–132. doi:10.1016/j.carrev.2022.05.032
   PubMed Web of Science ®Google Scholar
• van Hemert ND, Rozemeijer R, Voskuil M, et al. Clinical outcomes after permanent polymer or polymer-free stent implantation in patients with diabetes mellitus: the ReCre8 diabetes substudy. Catheter Cardiovasc Interv. 2022;99(2):366–372. doi:10.1002/ccd.29685
   PubMed Web of Science ®Google Scholar
• Koch T, Lenz T, Joner M, et al. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus: results of the intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol- and zotarolimus-eluting stents (ISAR-TEST 5) trial. Clin Res Cardiol. 2021;110(10):1586–1598. doi:10.1007/s00392-021-01854-7
   PubMedGoogle Scholar
• Hansen KN, Maeng M, Raungaard B, et al. Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial. Catheter Cardiovasc Interv. 2022;99(4):1095–1103. doi:10.1002/ccd.30090
   PubMed Web of Science ®Google Scholar
• Richardt G, Maillard L, Nazzaro MS, et al. Polymer-free drug-coated coronary stents in diabetic patients at high bleeding risk: a pre-specified sub-study of the LEADERS FREE trial. Clin Res Cardiol. 2019;108(1):31–38. doi:10.1007/s00392-018-1308-1
   PubMed Web of Science ®Google Scholar
• Romaguera R, Salinas P, Gomez-Lara J, et al. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. Eur Heart J. 2022;43(13):1320–1330. doi:10.1093/eurheartj/ehab790
   PubMed Web of Science ®Google Scholar
• Romaguera SP, P Salinas, S Brugaletta, et al. Two-year outcomes of the randomized second-generation drug-eluting stents in diabetes (SUGAR) trial. Paper presented at TCT. Boston, MA; 2022.
   Google Scholar
• Windecker S, Latib A, Kedhi E, et al. Polymer-based versus polymer-free stents in high bleeding risk patients: final 2-year results from Onyx ONE. JACC Cardiovasc Interv. 2022;15(11):1153–1163. doi:10.1016/j.jcin.2022.04.010
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Brit Med J. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. doi:10.1136/ebmental-2019-300117
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Software. 2010;36(3):1–48. doi:10.18637/jss.v036.i03
   Web of Science ®Google Scholar
• Higgins JPT, López-López JA, Becker BJ, et al. Synthesising quantitative evidence in systematic reviews of complex health interventions. BMJ Glob Health. 2019;4(Suppl. 1):e000858. doi:10.1136/bmjgh-2018-000858
   PubMed Web of Science ®Google Scholar
• Bhanvadia VM, Desai NJ, Agarwal NM. Study of coronary atherosclerosis by modified American heart association classification of atherosclerosis -an autopsy study. J Clin Diagn Res. 2013;7(11):2494–2497. doi:10.7860/JCDR/2013/6828.3588
   PubMedGoogle Scholar
• Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62(3):181–190. doi:10.1016/j.jacc.2013.04.045
   PubMed Web of Science ®Google Scholar
• Wang H, Xie X, Zu Q, et al. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis. Cardiovasc Diabetol. 2022;21(1):220. doi:10.1186/s12933-022-01673-8
   PubMed Web of Science ®Google Scholar
• Hassan S, Ali MN, Ghafoor B. Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach. J Cardiothorac Surg. 2022;17(1):65. doi:10.1186/s13019-022-01812-y
   PubMed Web of Science ®Google Scholar
• Wiemer M, Butz T, Schmidt W, et al. Scanning electron microscopic analysis of different drug eluting stents after failed implantation: from nearly undamaged to major damaged polymers. Catheter Cardiovasc Interv. 2010;75(6):905–911. doi:10.1002/ccd.22347
   PubMed Web of Science ®Google Scholar
• Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109(16):1948–1954. doi:10.1161/01.CIR.0000127129.94129.6F
   PubMed Web of Science ®Google Scholar
• Achim A, Alampi C, Krivoshei L, et al. In vitro effect of intravascular lithotripsy on the polymer of a drug-eluting stent. EuroIntervention. 2022;18(4):e333–e334. doi:10.4244/EIJ-D-22-00300
   PubMed Web of Science ®Google Scholar
• Beatty B, Shin D, Wolff E, et al. Quantitative in vitro investigation of polymer damage on drug-eluting stents resulting from intravascular lithotripsy. JACC Cardiovasc Interv. 2024;17(2):320–322. doi:10.1016/j.jcin.2023.10.007
   PubMed Web of Science ®Google Scholar
• Schurgin S, Rich S, Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care. 2001;24(2):335–338. doi:10.2337/diacare.24.2.335
   PubMed Web of Science ®Google Scholar
• Montone RA, Pitocco D, Gurgoglione FL, et al. Microvascular complications identify a specific coronary atherosclerotic phenotype in patients with Type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):211. doi:10.1186/s12933-022-01637-y
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Yamamoto E, Bryniarski K, et al. Coronary plaque characteristics in patients with diabetes mellitus who presented with acute coronary syndromes. J Am Heart Assoc. 2018;7(14):e009245. doi:10.1161/JAHA.118.009245
   PubMed Web of Science ®Google Scholar
• Haas AV, McDonnell ME. Pathogenesis of cardiovascular disease in diabetes. Endocrinol Metab Clin North Am. 2018;47(1):51–63. doi:10.1016/j.ecl.2017.10.010
   PubMed Web of Science ®Google Scholar
• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar